Spyre therapeutics to participate in the 7th annual evercore isi healthconx conference

Waltham, mass. , nov. 25, 2024 /prnewswire/ -- spyre therapeutics, inc. (nasdaq: syre), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("ibd"), today announced that will participate in a fireside chat and investor meetings at the 7th annual evercore isi healthconx conference.
EVR Ratings Summary
EVR Quant Ranking